Cryopyrin-Associated Periodic Syndrome Drug Pipeline Report 2024: Therapeutic Developments for Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, and Mabpharm
Yahoo FinanceApr 25 07:43 ET
Express News | Aclaris Therapeutics Inc - Manion Succeeds Interim CEO Abbie Celniker Who Will Continue to Serve as Chair of Company's Board of Directors
Moomoo 24/7Apr 23 08:00 ET
Express News | Flare Therapeutics Appoints Douglas Manion, M.d., Frcp (C) as Chief Executive Officer
Moomoo 24/7Apr 23 08:00 ET
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
Yahoo FinanceApr 11 10:12 ET
Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - Featuring Eli Lilly & Company, Amgen, Johnson & Johnson, and Aclaris Therapeutics Among Others
Yahoo FinanceApr 8 10:42 ET
Biotech's Role in Addressing the Pancreatic Cancer Emergency
USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today....
PR NewswireMar 14 08:45 ET
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
BenzingaMar 6 06:56 ET
Aclaris Therapeutics(ACRS.US) Director Buys US$17,955 in Common Stocks
$Aclaris Therapeutics(ACRS.US)$ Director Powell Andrew Kenneth William purchased 14,500 shares of Common Stocks on Mar 1, 4, 2024 at an average price of $1.24 for a total value of $17,955.Source: Anno
moomoo NewsMar 5 17:43 ET
Aclaris (ACRS) Upgraded to Buy: Here's Why
Yahoo FinanceMar 4 12:00 ET
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Yahoo FinanceMar 4 09:40 ET
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
TipRanksMar 4 06:31 ET
Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential
TipRanksMar 4 06:30 ET
Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks
TipRanksMar 1 01:08 ET
Aclaris Therapeutics: Q4 Earnings Insights
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q4 earnings results on Tuesday, February 27, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsAclaris Therapeutics bea
BenzingaFeb 27 08:55 ET
Aclaris Therapeutics GAAP EPS of -$0.02 Beats by $0.31, Revenue of $17.6M Beats by $12.55M
Seeking AlphaFeb 27 07:17 ET
Aclaris Therapeutics 4Q Loss $1.49M >ACRS
Aclaris Therapeutics 4Q Loss $1.49M >ACRS
Dow JonesFeb 27 07:00 ET
Press Release: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS
Dow JonesFeb 27 07:00 ET
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
PDF Version Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update February 27, 2024 WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ac
Aclaris TherapeuticsFeb 27 00:00 ET
Aclaris Therapeutics Executive Team Undergoes Major Changes
TipRanksFeb 6 04:53 ET
HW Wainwright Cuts Aclaris to Neutral, Cites Underwhelming Study Data
Seeking AlphaJan 22 17:55 ET
No Data
No Data